Literature DB >> 18197934

Relationship between expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in esophageal carcinoma cell lines.

T Ando1, H Ishiguro, Y Kuwabara, M Kimura, A Mitsui, N Sugito, R Mori, R Ogawa, T Katada, Y Fujii.   

Abstract

5-Fluorouracil (5-FU) is a key drug in the treatment of esophageal squamous cell carcinoma (ESCC). Gene expression of 5-FU metabolic enzymes such as thymidylate synthase (TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase (DPD) and orotate phosphoribosyl transferase (OPRT), has recently been investigated in order to predict the 5-FU sensitivity of several cancers. We examined the relationship between such gene expression and 5-FU sensitivity in 25 ESCC cell lines. TS, DPD, TP and OPRT mRNA levels were assessed by real-time polymerase chain reaction. The 50% inhibitory concentrations (IC50) of 5-FU in 25 ESCC cell lines were determined by cell proliferation assay. IC50 values for 5-FU ranged from 1.00 to 39.81 micromol/L. There were significant positive correlations between IC50 and TS mRNA expression (R(2) = 0.5781, P < 0.0001) and DPD mRNA expression (R(2) = 0.3573, P = 0.0016). There were no correlations between IC50 and TP or OPRT mRNA expression. TS and DPD mRNA expression levels may be useful indicators in predicting the anti-tumor activity of 5-FU in ESCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18197934     DOI: 10.1111/j.1442-2050.2007.00700.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  13 in total

1.  Novel 5-fluorouracil-resistant human esophageal squamous cell carcinoma cells with dihydropyrimidine dehydrogenase overexpression.

Authors:  Osamu Kikuchi; Shinya Ohashi; Yukie Nakai; Shunsaku Nakagawa; Kazuaki Matsuoka; Takashi Kobunai; Teiji Takechi; Yusuke Amanuma; Masahiro Yoshioka; Tomomi Ida; Yoshihiro Yamamoto; Yasushi Okuno; Shin'ichi Miyamoto; Hiroshi Nakagawa; Kazuo Matsubara; Tsutomu Chiba; Manabu Muto
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells.

Authors:  Dimitrios J Stravopodis; Panagiotis K Karkoulis; Eumorphia G Konstantakou; Sophia Melachroinou; Angeliki Thanasopoulou; Gerasimos Aravantinos; Lukas H Margaritis; Ema Anastasiadou; Gerassimos E Voutsinas
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-28       Impact factor: 4.553

3.  Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.

Authors:  Chariya Hahnvajanawong; Jariya Chaiyagool; Wunchana Seubwai; Vajarabhongsa Bhudhisawasdi; Nisana Namwat; Narong Khuntikeo; Banchob Sripa; Ake Pugkhem; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

4.  Thymidylate synthetase and dihydropyrimidine dehydrogenase mRNA levels in esophageal cancer.

Authors:  Masahiro Kimura; Yoshiyuki Kuwabara; Akira Mitsui; Hideyuki Ishiguro; Nobuyoshi Sugito; Tatsuya Tanaka; Midori Shiozaki; Yasuhiro Naganawa; Hiromitsu Takeyama
Journal:  Oncol Lett       Date:  2010-12-16       Impact factor: 2.967

Review 5.  Molecular mechanisms associated with chemoresistance in esophageal cancer.

Authors:  Matheus Lohan-Codeço; Maria Luísa Barambo-Wagner; Luiz Eurico Nasciutti; Luis Felipe Ribeiro Pinto; Nathalia Meireles Da Costa; Antonio Palumbo
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

6.  PAK6 increase chemoresistance and is a prognostic marker for stage II and III colon cancer patients undergoing 5-FU based chemotherapy.

Authors:  Jian Chen; Huijun Lu; Dongwang Yan; Feifei Cui; Xiaoliang Wang; Fudong Yu; Yingming Xue; Xiaodong Feng; Jingtao Wang; Xiao Wang; Tao Jiang; Meng Zhang; Senlin Zhao; Yang Yu; Huamei Tang; Zhihai Peng
Journal:  Oncotarget       Date:  2015-01-01

Review 7.  Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers.

Authors:  Björn L D M Brücher; Yan Li; Philipp Schnabel; Martin Daumer; Timothy J Wallace; Rainer Kube; Bruno Zilberstein; Scott Steele; Jan L A Voskuil; Ijaz S Jamall
Journal:  Clin Transl Med       Date:  2016-04-06

8.  Three-dimensional perfused tumour spheroid model for anti-cancer drug screening.

Authors:  Xiao Wan; Zhaohui Li; Hua Ye; Zhanfeng Cui
Journal:  Biotechnol Lett       Date:  2016-05-11       Impact factor: 2.461

9.  Factors affecting the sensitivity of human-derived esophageal carcinoma cell lines to 5-fluorouracil and cisplatin.

Authors:  Tetsuya Minegaki; Kohji Takara; Ryohei Hamaguchi; Masayuki Tsujimoto; Kohshi Nishiguchi
Journal:  Oncol Lett       Date:  2012-11-05       Impact factor: 2.967

10.  Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas.

Authors:  Taemoon Chung; Juri Na; Young-Il Kim; Da-Young Chang; Young Il Kim; Hyeonjin Kim; Ho Eun Moon; Keon Wook Kang; Dong Soo Lee; June-Key Chung; Sung-Soo Kim; Haeyoung Suh-Kim; Sun Ha Paek; Hyewon Youn
Journal:  Theranostics       Date:  2016-06-17       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.